APO Research
Talk to an analyst

APO RESEARCH · REPORT

Relapsed Acute Myeloid Leukemia Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Relapsed Acute Myeloid Leukemia Drug Market Analysis and Forecast 2026-2032

19 December 2025207 pages

Choose your research edition.

Industry ResearchRelapsed Acute Myeloid Leukemia Drug Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Relapsed Acute Myeloid Leukemia Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Relapsed Acute Myeloid Leukemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Relapsed Acute Myeloid Leukemia Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Relapsed Acute Myeloid Leukemia Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Relapsed Acute Myeloid Leukemia Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Relapsed Acute Myeloid Leukemia Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Relapsed Acute Myeloid Leukemia Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Relapsed Acute Myeloid Leukemia Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Relapsed Acute Myeloid Leukemia Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Relapsed Acute Myeloid Leukemia Drug include 4SC AG, Amgen Inc., AbbVie Inc., AstraZeneca Plc, CTI BioPharma Corp., Cornerstone Pharmaceuticals, Inc., Celgene Corporation, Calithera Biosciences, Inc. and Bristol-Myers Squibb Company, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Relapsed Acute Myeloid Leukemia Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Relapsed Acute Myeloid Leukemia Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Relapsed Acute Myeloid Leukemia Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Relapsed Acute Myeloid Leukemia Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Relapsed Acute Myeloid Leukemia Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Relapsed Acute Myeloid Leukemia Drug sales, projected growth trends, production technology, application and end-user industry.

Relapsed Acute Myeloid Leukemia Drug Segment by Company

4SC AG

Amgen Inc.

AbbVie Inc.

AstraZeneca Plc

CTI BioPharma Corp.

Cornerstone Pharmaceuticals, Inc.

Celgene Corporation

Calithera Biosciences, Inc.

Bristol-Myers Squibb Company

Boston Biomedical, Inc.

Boehringer Ingelheim GmbH

BioLineRx, Ltd.

AVEO Pharmaceuticals, Inc.

Astex Pharmaceuticals, Inc.

Astellas Pharma Inc.

Array BioPharma Inc.

Arog Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Relapsed Acute Myeloid Leukemia Drug Segment by Type

aNK Program

AT-9283

BI-836858

BL-8040

Binimetinib

Others

Relapsed Acute Myeloid Leukemia Drug Segment by Application

Clinic

Hospital

Others

Relapsed Acute Myeloid Leukemia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Relapsed Acute Myeloid Leukemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Relapsed Acute Myeloid Leukemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Relapsed Acute Myeloid Leukemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Relapsed Acute Myeloid Leukemia Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Relapsed Acute Myeloid Leukemia Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Relapsed Acute Myeloid Leukemia Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. aNK Program Major Manufacturers Table 3. AT-9283 Major Manufacturers Table 4. BI-836858 Major Manufacturers Table 5. BL-8040 Major Manufacturers Table 6. Binimetinib Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Clinic Major Manufacturers Table 10. Hospital Major Manufacturers Table 11. Others Major Manufacturers Table 12. Relapsed Acute Myeloid Leukemia Drug Industry Trends Table 13. Relapsed Acute Myeloid Leukemia Drug Industry Drivers Table 14. Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges Table 15. Relapsed Acute Myeloid Leukemia Drug Industry Restraints Table 16. Global Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2021-2026) Table 20. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2027-2032) Table 21. Global Relapsed Acute Myeloid Leukemia Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2026) & (K Units) Table 23. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2027-2032) & (K Units) Table 24. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2021-2026) Table 25. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2027-2032) Table 26. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers (2021-2026) Table 30. Global Relapsed Acute Myeloid Leukemia Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Relapsed Acute Myeloid Leukemia Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Relapsed Acute Myeloid Leukemia Drug Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers, Product Type & Application Table 34. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Relapsed Acute Myeloid Leukemia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2021-2026) Table 41. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2027-2032) Table 42. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 44. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2027-2032) & (K Units) Table 45. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2021-2026) Table 46. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2027-2032) Table 47. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2021-2026) & (US$/Unit) Table 48. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2027-2032) & (US$/Unit) Table 49. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2021-2026) Table 53. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2027-2032) Table 54. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 56. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2027-2032) & (K Units) Table 57. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2021-2026) Table 58. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2027-2032) Table 59. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2027-2032) & (US$/Unit) Table 61. 4SC AG Company Information Table 62. 4SC AG Business Overview Table 63. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 65. 4SC AG Recent Development Table 66. Amgen Inc. Company Information Table 67. Amgen Inc. Business Overview Table 68. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 70. Amgen Inc. Recent Development Table 71. AbbVie Inc. Company Information Table 72. AbbVie Inc. Business Overview Table 73. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 75. AbbVie Inc. Recent Development Table 76. AstraZeneca Plc Company Information Table 77. AstraZeneca Plc Business Overview Table 78. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 80. AstraZeneca Plc Recent Development Table 81. CTI BioPharma Corp. Company Information Table 82. CTI BioPharma Corp. Business Overview Table 83. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 85. CTI BioPharma Corp. Recent Development Table 86. Cornerstone Pharmaceuticals, Inc. Company Information Table 87. Cornerstone Pharmaceuticals, Inc. Business Overview Table 88. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 90. Cornerstone Pharmaceuticals, Inc. Recent Development Table 91. Celgene Corporation Company Information Table 92. Celgene Corporation Business Overview Table 93. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 95. Celgene Corporation Recent Development Table 96. Calithera Biosciences, Inc. Company Information Table 97. Calithera Biosciences, Inc. Business Overview Table 98. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 100. Calithera Biosciences, Inc. Recent Development Table 101. Bristol-Myers Squibb Company Company Information Table 102. Bristol-Myers Squibb Company Business Overview Table 103. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 105. Bristol-Myers Squibb Company Recent Development Table 106. Boston Biomedical, Inc. Company Information Table 107. Boston Biomedical, Inc. Business Overview Table 108. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 110. Boston Biomedical, Inc. Recent Development Table 111. Boehringer Ingelheim GmbH Company Information Table 112. Boehringer Ingelheim GmbH Business Overview Table 113. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 115. Boehringer Ingelheim GmbH Recent Development Table 116. BioLineRx, Ltd. Company Information Table 117. BioLineRx, Ltd. Business Overview Table 118. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 120. BioLineRx, Ltd. Recent Development Table 121. AVEO Pharmaceuticals, Inc. Company Information Table 122. AVEO Pharmaceuticals, Inc. Business Overview Table 123. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 125. AVEO Pharmaceuticals, Inc. Recent Development Table 126. Astex Pharmaceuticals, Inc. Company Information Table 127. Astex Pharmaceuticals, Inc. Business Overview Table 128. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 130. Astex Pharmaceuticals, Inc. Recent Development Table 131. Astellas Pharma Inc. Company Information Table 132. Astellas Pharma Inc. Business Overview Table 133. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 135. Astellas Pharma Inc. Recent Development Table 136. Array BioPharma Inc. Company Information Table 137. Array BioPharma Inc. Business Overview Table 138. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 140. Array BioPharma Inc. Recent Development Table 141. Arog Pharmaceuticals, Inc. Company Information Table 142. Arog Pharmaceuticals, Inc. Business Overview Table 143. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 145. Arog Pharmaceuticals, Inc. Recent Development Table 146. Agios Pharmaceuticals, Inc. Company Information Table 147. Agios Pharmaceuticals, Inc. Business Overview Table 148. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 150. Agios Pharmaceuticals, Inc. Recent Development Table 151. Actinium Pharmaceuticals, Inc. Company Information Table 152. Actinium Pharmaceuticals, Inc. Business Overview Table 153. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 155. Actinium Pharmaceuticals, Inc. Recent Development Table 156. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2026) & (US$ Million) Table 157. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2027-2032) & (US$ Million) Table 158. North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 159. North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2027-2032) & (K Units) Table 160. North America Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 161. North America Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 162. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2026) & (US$ Million) Table 163. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2027-2032) & (US$ Million) Table 164. North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 165. North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2027-2032) & (K Units) Table 166. North America Relapsed Acute Myeloid Leukemia Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 167. North America Relapsed Acute Myeloid Leukemia Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 168. North America Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. North America Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 170. North America Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 171. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 172. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 173. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 174. North America Relapsed Acute Myeloid Leukemia Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 175. North America Relapsed Acute Myeloid Leukemia Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 176. United States Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 177. Canada Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 178. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2026) & (US$ Million) Table 179. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2027-2032) & (US$ Million) Table 180. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 181. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2027-2032) & (K Units) Table 182. Europe Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 183. Europe Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 184. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2026) & (US$ Million) Table 185. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2027-2032) & (US$ Million) Table 186. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 187. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2027-2032) & (K Units) Table 188. Europe Relapsed Acute Myeloid Leukemia Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 189. Europe Relapsed Acute Myeloid Leukemia Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 190. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 191. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 192. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 193. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 194. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 195. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 196. Europe Relapsed Acute Myeloid Leukemia Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 197. Europe Relapsed Acute Myeloid Leukemia Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 198. Germany Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 199. France Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 200. U.K. Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 201. Italy Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 202. Netherlands Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 203. China Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2026) & (US$ Million) Table 204. China Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2027-2032) & (US$ Million) Table 205. China Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 206. China Relapsed Acute Myeloid Leukemia Drug Sales by Type (2027-2032) & (K Units) Table 207. China Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 208. China Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 209. China Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2026) & (US$ Million) Table 210. China Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2027-2032) & (US$ Million) Table 211. China Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 212. China Relapsed Acute Myeloid Leukemia Drug Sales by Application (2027-2032) & (K Units) Table 213. China Relapsed Acute Myeloid Leukemia Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 214. China Relapsed Acute Myeloid Leukemia Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 215. Asia Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2026) & (US$ Million) Table 216. Asia Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2027-2032) & (US$ Million) Table 217. Asia Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 218. Asia Relapsed Acute Myeloid Leukemia Drug Sales by Type (2027-2032) & (K Units) Table 219. Asia Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 220. Asia Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 221. Asia Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2026) & (US$ Million) Table 222. Asia Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2027-2032) & (US$ Million) Table 223. Asia Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 224. Asia Relapsed Acute Myeloid Leukemia Drug Sales by Application (2027-2032) & (K Units) Table 225. Asia Relapsed Acute Myeloid Leukemia Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 226. Asia Relapsed Acute Myeloid Leukemia Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 227. Asia Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 228. Asia Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 229. Asia Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 230. Asia Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 231. Asia Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 232. Asia Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 233. Asia Relapsed Acute Myeloid Leukemia Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 234. Asia Relapsed Acute Myeloid Leukemia Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 235. Japan Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 236. South Korea Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 237. India Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 238. Australia Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 239. China Taiwan Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 240. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 241. SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2026) & (US$ Million) Table 242. SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2027-2032) & (US$ Million) Table 243. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 244. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales by Type (2027-2032) & (K Units) Table 245. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 246. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 247. SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2026) & (US$ Million) Table 248. SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2027-2032) & (US$ Million) Table 249. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 250. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales by Application (2027-2032) & (K Units) Table 251. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 252. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 253. SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 254. SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 255. SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 256. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 257. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 258. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 259. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 260. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 261. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 262. Argentina Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 263. Chile Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 264. Colombia Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 265. Peru Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 266. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 267. Israel Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 268. UAE Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 269. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 270. Iran Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 271. Egypt Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Table 272. Key Raw Materials Table 273. Raw Materials Key Suppliers Table 274. Relapsed Acute Myeloid Leukemia Drug Distributors List Table 275. Relapsed Acute Myeloid Leukemia Drug Customers List Table 276. Research Programs/Design for This Report Table 277. Authors List of This Report Table 278. Secondary Sources Table 279. Primary Sources List of Figures Figure 1. Relapsed Acute Myeloid Leukemia Drug Image Figure 2. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Relapsed Acute Myeloid Leukemia Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. aNK Program Image Figure 5. AT-9283 Image Figure 6. BI-836858 Image Figure 7. BL-8040 Image Figure 8. Binimetinib Image Figure 9. Others Image Figure 10. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Relapsed Acute Myeloid Leukemia Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Clinic Image Figure 13. Hospital Image Figure 14. Others Image Figure 15. Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Figure 17. Global Relapsed Acute Myeloid Leukemia Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2021-2032) Figure 20. Global Relapsed Acute Myeloid Leukemia Drug Sales (2021-2032) & (K Units) Figure 21. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Relapsed Acute Myeloid Leukemia Drug Sales YoY (2021-2032) & (K Units) Figure 24. Europe Relapsed Acute Myeloid Leukemia Drug Sales YoY (2021-2032) & (K Units) Figure 25. China Relapsed Acute Myeloid Leukemia Drug Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) Relapsed Acute Myeloid Leukemia Drug Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales YoY (2021-2032) & (K Units) Figure 28. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2021-2032) Figure 34. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2021-2032) Figure 37. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2021-2032) Figure 40. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2021-2032) Figure 43. North America Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2021-2032) Figure 44. North America Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2021-2032) Figure 45. North America Relapsed Acute Myeloid Leukemia Drug Revenue Share by Application (2021-2032) Figure 46. North America Relapsed Acute Myeloid Leukemia Drug Sales Share by Application (2021-2032) Figure 47. North America Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country (2021-2032) Figure 48. North America Relapsed Acute Myeloid Leukemia Drug Sales Share by Country (2021-2032) Figure 49. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2021-2032) Figure 50. Europe Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2021-2032) Figure 51. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Share by Application (2021-2032) Figure 52. Europe Relapsed Acute Myeloid Leukemia Drug Sales Share by Application (2021-2032) Figure 53. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country (2021-2032) Figure 54. Europe Relapsed Acute Myeloid Leukemia Drug Sales Share by Country (2021-2032) Figure 55. China Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2021-2032) Figure 56. China Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2021-2032) Figure 57. China Relapsed Acute Myeloid Leukemia Drug Revenue Share by Application (2021-2032) Figure 58. China Relapsed Acute Myeloid Leukemia Drug Sales Share by Application (2021-2032) Figure 59. Asia Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2021-2032) Figure 60. Asia Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2021-2032) Figure 61. Asia Relapsed Acute Myeloid Leukemia Drug Revenue Share by Application (2021-2032) Figure 62. Asia Relapsed Acute Myeloid Leukemia Drug Sales Share by Application (2021-2032) Figure 63. Asia Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country (2021-2032) Figure 64. Asia Relapsed Acute Myeloid Leukemia Drug Sales Share by Country (2021-2032) Figure 65. SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2021-2032) Figure 66. SAMEA Relapsed Acute Myeloid Leukemia Drug Sales Share by Type (2021-2032) Figure 67. SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue Share by Application (2021-2032) Figure 68. SAMEA Relapsed Acute Myeloid

Scope & coverage.

Types
  • aNK Program
  • AT-9283
  • BI-836858
  • BL-8040
  • Binimetinib
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • 4SC AG
  • Amgen Inc.
  • AbbVie Inc.
  • AstraZeneca Plc
  • CTI BioPharma Corp.
  • Cornerstone Pharmaceuticals, Inc.
  • Celgene Corporation
  • Calithera Biosciences, Inc.
  • Bristol-Myers Squibb Company
  • Boston Biomedical, Inc.
  • Boehringer Ingelheim GmbH
  • BioLineRx, Ltd.
  • AVEO Pharmaceuticals, Inc.
  • Astex Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Array BioPharma Inc.
  • Arog Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Relapsed Acute Myeloid Leukemia Drug Market by Type
  3. 1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 aNK Program
  5. 1.2.3 AT-9283
  6. 1.2.4 BI-836858
  7. 1.2.5 BL-8040
  8. 1.2.6 Binimetinib
  9. 1.2.7 Others
  10. 1.3 Relapsed Acute Myeloid Leukemia Drug Market by Application
  11. 1.3.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Clinic
  13. 1.3.3 Hospital
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Relapsed Acute Myeloid Leukemia Drug Market Dynamics
  1. 2.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
  2. 2.2 Relapsed Acute Myeloid Leukemia Drug Industry Drivers
  3. 2.3 Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges
  4. 2.4 Relapsed Acute Myeloid Leukemia Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region
  3. 3.2.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region
  9. 3.4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers
  2. 4.1.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers
  6. 4.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Relapsed Acute Myeloid Leukemia Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Relapsed Acute Myeloid Leukemia Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Relapsed Acute Myeloid Leukemia Drug Manufacturers, Product Type & Application
  13. 4.7 Global Relapsed Acute Myeloid Leukemia Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Relapsed Acute Myeloid Leukemia Drug Market CR5 and HHI
  16. 4.8.2 2025 Relapsed Acute Myeloid Leukemia Drug Tier 1, Tier 2, and Tier 3
5 Relapsed Acute Myeloid Leukemia Drug Market by Type
  1. 5.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type
  2. 5.1.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type
  6. 5.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type
6 Relapsed Acute Myeloid Leukemia Drug Market by Application
  1. 6.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application
  2. 6.1.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application
  6. 6.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Application
7 Company Profiles
  1. 7.1 4SC AG
  2. 7.1.1 4SC AG Company Information
  3. 7.1.2 4SC AG Business Overview
  4. 7.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  6. 7.1.5 4SC AG Recent Developments
  7. 7.2 Amgen Inc.
  8. 7.2.1 Amgen Inc. Company Information
  9. 7.2.2 Amgen Inc. Business Overview
  10. 7.2.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  12. 7.2.5 Amgen Inc. Recent Developments
  13. 7.3 AbbVie Inc.
  14. 7.3.1 AbbVie Inc. Company Information
  15. 7.3.2 AbbVie Inc. Business Overview
  16. 7.3.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  18. 7.3.5 AbbVie Inc. Recent Developments
  19. 7.4 AstraZeneca Plc
  20. 7.4.1 AstraZeneca Plc Company Information
  21. 7.4.2 AstraZeneca Plc Business Overview
  22. 7.4.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  24. 7.4.5 AstraZeneca Plc Recent Developments
  25. 7.5 CTI BioPharma Corp.
  26. 7.5.1 CTI BioPharma Corp. Company Information
  27. 7.5.2 CTI BioPharma Corp. Business Overview
  28. 7.5.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  30. 7.5.5 CTI BioPharma Corp. Recent Developments
  31. 7.6 Cornerstone Pharmaceuticals, Inc.
  32. 7.6.1 Cornerstone Pharmaceuticals, Inc. Company Information
  33. 7.6.2 Cornerstone Pharmaceuticals, Inc. Business Overview
  34. 7.6.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  36. 7.6.5 Cornerstone Pharmaceuticals, Inc. Recent Developments
  37. 7.7 Celgene Corporation
  38. 7.7.1 Celgene Corporation Company Information
  39. 7.7.2 Celgene Corporation Business Overview
  40. 7.7.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  42. 7.7.5 Celgene Corporation Recent Developments
  43. 7.8 Calithera Biosciences, Inc.
  44. 7.8.1 Calithera Biosciences, Inc. Company Information
  45. 7.8.2 Calithera Biosciences, Inc. Business Overview
  46. 7.8.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  48. 7.8.5 Calithera Biosciences, Inc. Recent Developments
  49. 7.9 Bristol-Myers Squibb Company
  50. 7.9.1 Bristol-Myers Squibb Company Company Information
  51. 7.9.2 Bristol-Myers Squibb Company Business Overview
  52. 7.9.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  54. 7.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 7.10 Boston Biomedical, Inc.
  56. 7.10.1 Boston Biomedical, Inc. Company Information
  57. 7.10.2 Boston Biomedical, Inc. Business Overview
  58. 7.10.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  60. 7.10.5 Boston Biomedical, Inc. Recent Developments
  61. 7.11 Boehringer Ingelheim GmbH
  62. 7.11.1 Boehringer Ingelheim GmbH Company Information
  63. 7.11.2 Boehringer Ingelheim GmbH Business Overview
  64. 7.11.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  66. 7.11.5 Boehringer Ingelheim GmbH Recent Developments
  67. 7.12 BioLineRx, Ltd.
  68. 7.12.1 BioLineRx, Ltd. Company Information
  69. 7.12.2 BioLineRx, Ltd. Business Overview
  70. 7.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  72. 7.12.5 BioLineRx, Ltd. Recent Developments
  73. 7.13 AVEO Pharmaceuticals, Inc.
  74. 7.13.1 AVEO Pharmaceuticals, Inc. Company Information
  75. 7.13.2 AVEO Pharmaceuticals, Inc. Business Overview
  76. 7.13.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  78. 7.13.5 AVEO Pharmaceuticals, Inc. Recent Developments
  79. 7.14 Astex Pharmaceuticals, Inc.
  80. 7.14.1 Astex Pharmaceuticals, Inc. Company Information
  81. 7.14.2 Astex Pharmaceuticals, Inc. Business Overview
  82. 7.14.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  84. 7.14.5 Astex Pharmaceuticals, Inc. Recent Developments
  85. 7.15 Astellas Pharma Inc.
  86. 7.15.1 Astellas Pharma Inc. Company Information
  87. 7.15.2 Astellas Pharma Inc. Business Overview
  88. 7.15.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  90. 7.15.5 Astellas Pharma Inc. Recent Developments
  91. 7.16 Array BioPharma Inc.
  92. 7.16.1 Array BioPharma Inc. Company Information
  93. 7.16.2 Array BioPharma Inc. Business Overview
  94. 7.16.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  96. 7.16.5 Array BioPharma Inc. Recent Developments
  97. 7.17 Arog Pharmaceuticals, Inc.
  98. 7.17.1 Arog Pharmaceuticals, Inc. Company Information
  99. 7.17.2 Arog Pharmaceuticals, Inc. Business Overview
  100. 7.17.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  102. 7.17.5 Arog Pharmaceuticals, Inc. Recent Developments
  103. 7.18 Agios Pharmaceuticals, Inc.
  104. 7.18.1 Agios Pharmaceuticals, Inc. Company Information
  105. 7.18.2 Agios Pharmaceuticals, Inc. Business Overview
  106. 7.18.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  108. 7.18.5 Agios Pharmaceuticals, Inc. Recent Developments
  109. 7.19 Actinium Pharmaceuticals, Inc.
  110. 7.19.1 Actinium Pharmaceuticals, Inc. Company Information
  111. 7.19.2 Actinium Pharmaceuticals, Inc. Business Overview
  112. 7.19.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  114. 7.19.5 Actinium Pharmaceuticals, Inc. Recent Developments
8 North America
  1. 8.1 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Type
  2. 8.1.1 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Relapsed Acute Myeloid Leukemia Drug Price by Type (2021-2032)
  5. 8.2 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Application
  6. 8.2.1 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Relapsed Acute Myeloid Leukemia Drug Price by Application (2021-2032)
  9. 8.3 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
  10. 8.3.1 North America Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Relapsed Acute Myeloid Leukemia Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Type
  2. 9.1.1 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Relapsed Acute Myeloid Leukemia Drug Price by Type (2021-2032)
  5. 9.2 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Application
  6. 9.2.1 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Relapsed Acute Myeloid Leukemia Drug Price by Application (2021-2032)
  9. 9.3 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country
  10. 9.3.1 Europe Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Relapsed Acute Myeloid Leukemia Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Relapsed Acute Myeloid Leukemia Drug Market Size by Type
  2. 10.1.1 China Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2032)
  4. 10.1.3 China Relapsed Acute Myeloid Leukemia Drug Price by Type (2021-2032)
  5. 10.2 China Relapsed Acute Myeloid Leukemia Drug Market Size by Application
  6. 10.2.1 China Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2032)
  8. 10.2.3 China Relapsed Acute Myeloid Leukemia Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Relapsed Acute Myeloid Leukemia Drug Market Size by Type
  2. 11.1.1 Asia Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Relapsed Acute Myeloid Leukemia Drug Price by Type (2021-2032)
  5. 11.2 Asia Relapsed Acute Myeloid Leukemia Drug Market Size by Application
  6. 11.2.1 Asia Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Relapsed Acute Myeloid Leukemia Drug Price by Application (2021-2032)
  9. 11.3 Asia Relapsed Acute Myeloid Leukemia Drug Market Size by Country
  10. 11.3.1 Asia Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Relapsed Acute Myeloid Leukemia Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Relapsed Acute Myeloid Leukemia Drug Market Size by Type
  2. 12.1.1 SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Relapsed Acute Myeloid Leukemia Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Relapsed Acute Myeloid Leukemia Drug Market Size by Application
  6. 12.2.1 SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Relapsed Acute Myeloid Leukemia Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Relapsed Acute Myeloid Leukemia Drug Market Size by Country
  10. 12.3.1 SAMEA Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Relapsed Acute Myeloid Leukemia Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Relapsed Acute Myeloid Leukemia Drug Value Chain Analysis
  2. 13.1.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Relapsed Acute Myeloid Leukemia Drug Production Mode & Process
  6. 13.2 Relapsed Acute Myeloid Leukemia Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Relapsed Acute Myeloid Leukemia Drug Distributors
  9. 13.2.3 Relapsed Acute Myeloid Leukemia Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst